A preclinical study of spontaneously hypertensive rats found that MCP-mediated Gal3 inhibition attenuated early kidney damage independent of blood pressure levels, as evidenced by reduced albuminuria and improved kidney function, as well as decreased interstitial fibrosis, epithelial-mesenchymal transition, and inflammation on kidney biopsy (Martinez-Martinez et al., 2018). The gene discussed is LGALS3; the disease is Nephropathy.